Drug profile · INN
sulfisoxazole acetyl
GANTRISIN PEDIATRIC
sulfisoxazole acetyl (GANTRISIN PEDIATRIC) is a bacterial dihydropteroate synthase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — sulfisoxazole acetyl
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
sulfisoxazole acetyl (GANTRISIN PEDIATRIC) is a bacterial dihydropteroate synthase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial dihydropteroate synthase inhibitor
Primary target: Dihydropteroate synthase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is sulfisoxazole acetyl?
sulfisoxazole acetyl (GANTRISIN PEDIATRIC) is a bacterial dihydropteroate synthase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for sulfisoxazole acetyl?
GANTRISIN PEDIATRIC is a marketed brand name for sulfisoxazole acetyl. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of sulfisoxazole acetyl?
sulfisoxazole acetyl has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.